CN102247344A - Novel blood pressure reducing composition - Google Patents
Novel blood pressure reducing composition Download PDFInfo
- Publication number
- CN102247344A CN102247344A CN2011101418478A CN201110141847A CN102247344A CN 102247344 A CN102247344 A CN 102247344A CN 2011101418478 A CN2011101418478 A CN 2011101418478A CN 201110141847 A CN201110141847 A CN 201110141847A CN 102247344 A CN102247344 A CN 102247344A
- Authority
- CN
- China
- Prior art keywords
- unit consumption
- aliskiren
- pharmaceutical composition
- described pharmaceutical
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036772 blood pressure Effects 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 230000001603 reducing effect Effects 0.000 title abstract 4
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims abstract description 36
- 229960004601 aliskiren Drugs 0.000 claims abstract description 36
- 229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 12
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims abstract description 12
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims abstract description 12
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 12
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 4
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 claims description 13
- 229960000830 captopril Drugs 0.000 claims description 13
- 229950008554 levamlodipine Drugs 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 8
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- 229960004699 valsartan Drugs 0.000 claims description 8
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 8
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims description 7
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims description 7
- 229960001199 olmesartan medoxomil Drugs 0.000 claims description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000528 amlodipine Drugs 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 4
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 4
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 4
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 4
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 4
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 4
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 4
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims description 4
- 108010061435 Enalapril Proteins 0.000 claims description 4
- 108010007859 Lisinopril Proteins 0.000 claims description 4
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims description 4
- 229960004530 benazepril Drugs 0.000 claims description 4
- 229960004349 candesartan cilexetil Drugs 0.000 claims description 4
- 229960005227 delapril Drugs 0.000 claims description 4
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 4
- 229960000873 enalapril Drugs 0.000 claims description 4
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 4
- 229960004563 eprosartan Drugs 0.000 claims description 4
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 4
- 229960003580 felodipine Drugs 0.000 claims description 4
- 229960002490 fosinopril Drugs 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 229960002198 irbesartan Drugs 0.000 claims description 4
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004340 lacidipine Drugs 0.000 claims description 4
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims description 4
- 229960004294 lercanidipine Drugs 0.000 claims description 4
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims description 4
- 229960002394 lisinopril Drugs 0.000 claims description 4
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001597 nifedipine Drugs 0.000 claims description 4
- 229960005366 nilvadipine Drugs 0.000 claims description 4
- 229960003401 ramipril Drugs 0.000 claims description 4
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 4
- 229960005187 telmisartan Drugs 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000519 losartan potassium Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 229960003963 manidipine Drugs 0.000 claims description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000227 nisoldipine Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 239000000480 calcium channel blocker Substances 0.000 abstract description 3
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007935 oral tablet Substances 0.000 abstract 1
- 239000003087 receptor blocking agent Substances 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 241000700159 Rattus Species 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 102100030841 AT-rich interactive domain-containing protein 4A Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 101000792933 Homo sapiens AT-rich interactive domain-containing protein 4A Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- RSXGUJLKWYUPMC-UHFFFAOYSA-N flordipine Chemical compound CC1=C(C(=O)OCC)C(C=2C(=CC=CC=2)C(F)(F)F)C(C(=O)OCC)=C(C)N1CCN1CCOCC1 RSXGUJLKWYUPMC-UHFFFAOYSA-N 0.000 description 2
- 229950009366 flordipine Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002461 renin inhibitor Substances 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 229940086526 renin-inhibitors Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a novel blood pressure reducing composition. The blood pressure reducing composition is a medicinal composition of which active ingredients are any one or two of aliskiren and a medicinal salt thereof, a hydrate, a calcium channel blocker (CCB), an angiotensin type 1 (AT1) receptor blocker (ARB), an angiotensin-converting enzyme inhibitor (ACEI), hydrochlorothiazide and the like. The composition can be prepared into oral tablets or capsules and is used for treating hypertension, and the curative effect is superior to the blood pressure reducing effect of the independent aliskiren.
Description
Technical field
The present invention is a kind of novel blood pressure lowering compositions, belongs to medical technical field.
Background technology
Hypertension is the popular cardiovascular disease the most widely in the world today, it is again the important risk that causes coronary heart disease, apoplexy and renal failure, the hyperpietic not only has blood pressure to increase with hemodynamic unusual, and, belong to a kind of systemic disease often with the infringement of target organs such as sugar, lipid metabolic disorder and the heart, brain, kidney.Antihypertensive drug is more clinically, comprises diuretic, beta-Blocking agent, angiotensin converting enzyme inhibitor (ACE-I), Angiotensin II (AT II) receptor antagonist, calcium antagonist and α-Zu Zhiji.But they all have its certain limitation and side effect in the use.So side effect is little, better tolerance, and the antihypertensive of stable curative effect will be widely used as an ideal line depressor, and wherein stable curative effect, the little compound hypertension medicine of side effect also have been subjected to paying close attention to widely.
Aliskiren is a second filial generation renin inhibitor, acts on first rate-limiting step of renin-angiotensin-aldosterone system (RAS).All research datas all show at present, and aliskiren blood pressure lowering treatment has good safety and effectiveness, few side effects, long half time, taking convenience once a day.Aliskiren is the oral renin inhibitor of first kind of treatment hypertension and other cardiovascular disease and nephropathy.Aliskiren can effectively reduce light moderate hypertension patient's blood pressure level.And do not produce reflex tachycardia, do not influence cardiac function; Hypotensive effect is the feritin dependency, and therefore heavy dose of administration only can prolong action time, can not cause the blood pressure rapid drawdown.
Summary of the invention
The present invention is a kind of new blood pressure lowering compositions, it is characterized in that: be to be the Pharmaceutical composition of active component with aliskiren and pharmaceutical salts, hydrate and any 1-2 kind material as described below:
Material 1: calcium ion antagonist (CCB) comprises nifedipine, amlodipine, lercanidipine, felodipine, nilvadipine, lacidipine, nisoldipine and their pharmaceutical salts, optical isomer and hydrate;
Material 2:AT1 receptor antagonist (ARB) comprises valsartan, candesartan Cilexetil, olmesartan medoxomil, irbesartan, losartan, telmisartan, Eprosartan and their pharmaceutical salts, optical isomer and hydrate etc.;
Material 3: angiotensin converting enzyme inhibitor (ACEI) comprises captopril, lisinopril, ramipril, fosinopril, enalapril, benazepril, delapril and their pharmaceutical salts, optical isomer and hydrate etc.;
Material 4: hydrochlorothiazide
The preferred fumarate of the pharmaceutical salts of aliskiren.The pharmaceutical salts of calcium ion antagonist comprises hydrochlorate, mesylate, benzene sulfonate, maleate etc.
Preferred composition of the present invention is: aliskiren+Levamlodipine Besylate; Aliskiren+Levamlodipine Besylate+hydrochlorothiazide; Aliskiren+Levamlodipine Besylate+valsartan; Aliskiren+captopril, aliskiren+hydrochlorothiazide+captopril etc.;
The unit consumption of aliskiren is 37.5-1200mg, and preferred dose is 150-300mg;
The unit consumption of hydrochlorothiazide is 5-200mg, and preferred dose is 25-50mg;
The unit consumption of calcium ion antagonist (CCB) is: the unit consumption of (left side) amlodipine is 1.25-40mg, and preferred dose is 5-10mg; The unit consumption of nifedipine is 1.25-40mg, is preferably 5-10mg; The unit consumption of lercanidipine is 2.5-80mg, is preferably 10-20mg; The unit consumption of felodipine is 2.5-80mg, is preferably 10-20mg; The unit consumption of nilvadipine is 0.5-16mg, is preferably 2-4mg; The unit consumption of lacidipine is 1-24mg, is preferably 4-6mg;
The unit consumption of Manidipine is 1.25-40mg, is preferably 5-10mg.
The unit consumption of AT1 receptor antagonist (ARB) is: the unit consumption of olmesartan medoxomil is 5-160mg, is preferably 10-80mg;
The unit consumption of irbesartan is 37.5-600mg, is preferably 75-300mg; The unit consumption of candesartan Cilexetil is 1-32mg, is preferably 2-16mg; The unit consumption of Losartan Potassium is 12.5-200mg, is preferably 25-100mg; The unit consumption of telmisartan is 10-320mg, is preferably 20-160mg; The unit consumption of valsartan is 20-320mg, is preferably 40-160mg; The unit consumption of Eprosartan is 100-1200mg, is preferably 200-600mg.
The unit consumption of angiotensin converting enzyme inhibitor (ACEI) is: the unit consumption of captopril is 6.25-100mg, is preferably 12.5-50mg.The unit consumption of lisinopril is 5-80mg, is preferably 10-40mgmg; The unit consumption of ramipril is 0.5-20mg, is preferably 1.25-10mg; The unit consumption of fosinopril is 5-80mg, is preferably 10-40mg; The unit consumption of enalapril is 1.25-40mg, is preferably 2.5-20mg; The unit consumption of benazepril is 5-80mg, is preferably 10-40mg; 7 consumptions of the list of delapril are 15-120mg, are preferably 7.5-60mg.
Pharmaceutical composition of the present invention can be made into oral formulations, comprises granule, ordinary tablet, chewable tablet, dispersible tablet, oral cavity disintegration tablet, buccal tablet, capsule, soft capsule, drop pill, slow releasing tablet, slow releasing capsule etc.
The specific embodiment
Embodiment 1: tablet
| The supplementary material title | 1 | 2 | 3 | 4 | 5 |
| The fumaric acid aliskiren | 150g | 150g | 150g | 150g | 150g |
| The left-handed chlorine Flordipine of benzenesulfonic acid | 5g | 7.5g | 10g | ---- | ---- |
| Hydrochlorothiazide | ---- | 25g | ---- | ---- | 25g |
| Valsartan | ---- | ---- | 40g | ---- | ---- |
| Captopril | ---- | ---- | ---- | 25g | 12.5g |
| Microcrystalline Cellulose | 85g | 80g | 45g | 65g | 75g |
| Lactose | 36g | 36g | 36g | 36g | 36g |
| Sodium carboxymethyl cellulose | 10g | 10g | 10g | 10g | 10g |
| Pregelatinized Starch | 55g | 55g | 55g | 55g | 55g |
| Magnesium stearate | 1.6g | 1.6g | 1.6g | 1.6g | 1.6g |
| Purified water | In right amount | In right amount | In right amount | In right amount | In right amount |
Annotate: fumaric acid aliskiren specification is in aliskiren, and Levamlodipine besylate is in amlodipine
Technology: get each crude drug, morcelled 100 mesh sieves respectively, standby; Each adjuvant is crossed 60 mesh sieves respectively, and is standby; Except that magnesium stearate, get each supplementary material respectively, put mix homogeneously in the high-speed mixing granulating machine, add suitable quantity of water system soft material, 24 orders are granulated, 50 degree fluid bed dryings, 24 order granulate add magnesium stearate, mix homogeneously, tabletting carries out coating promptly to this plain sheet.
Embodiment 2: chewable tablet
| The supplementary material title | 1 | 2 | 3 | 4 | 5 |
| The fumaric acid aliskiren | 150g | 150g | 150g | 150g | 150g |
| The left-handed chlorine Flordipine of benzenesulfonic acid | 5g | 7.5g | 10g | ---- | ---- |
| Hydrochlorothiazide | ---- | 25g | ---- | ---- | 25g |
| Valsartan | ---- | ---- | 40g | ---- | ---- |
| Captopril | ---- | ---- | ---- | 25g | 12.5g |
| Mannitol | 205g | 195g | 160g | 185g | 175g |
| Sorbitol | 105g | 105g | 105g | 105g | 105g |
| Sodium carboxymethyl cellulose | 10g | 10g | 10g | 10g | 10g |
| Sucralose | 5g | 5g | 5g | 5g | 5g |
| Essence | In right amount | In right amount | In right amount | In right amount | In right amount |
| Magnesium stearate | 1.6g | 1.6g | 1.6g | 1.6g | 1.6g |
| Purified water | In right amount | In right amount | In right amount | In right amount | In right amount |
Annotate: fumaric acid aliskiren specification is in aliskiren, and Levamlodipine besylate is in amlodipine
Technology: get each supplementary material medicine, morcelled 100 mesh sieves respectively, standby; Except that magnesium stearate, get each supplementary material respectively, put mix homogeneously in the high-speed mixing granulating machine, add suitable quantity of water system soft material, 24 orders are granulated, 50 degree fluid bed dryings, 24 order granulate add magnesium stearate, mix homogeneously, tabletting, promptly.
Embodiment 3 curative effect confirmatory experiments
Below be the therapeutic evaluation experiment, further specify the curative effect advantage of the present composition.
1. experimental technique:
Get 110 of healthy male SD rats, after adaptability fed for 1 week. survey basic blood pressure with RBP-1 rat blood pressure instrument.Art fasting evening before yesterday 12h, inferior modeling in morning.All blood pressures is than before handling more than the high 2.66kPa (greater than 3 standard differences of normal arterial pressure) behind the modeling 4w, and is higher than 15.30kPa person and is defined as the high blood pressure disease model and forms.The rat of modeling success is divided at random: aliskiren (A), Levamlodipine Besylate (B1), aliskiren+Levamlodipine Besylate (B2); Aliskiren+Levamlodipine Besylate+hydrochlorothiazide (B3), olmesartan medoxomil (C1), aliskiren+olmesartan medoxomil (C2), aliskiren+olmesartan medoxomil+hydrochlorothiazide (C3), captopril (D1), aliskiren+captopril (D2), aliskiren+captopril+hydrochlorothiazide (D3), blank model group (O), other gets 10 of healthy SD rats, establishes the blank group.Matched group and blank model group are irritated stomach with 1ml/100g body weight normal saline, irritate stomach for all the other 3 groups and give relative medicine, and all with the normal saline preparation, irritate the stomach volume is the 1ml/100g body weight to medicine, 4 weeks of successive administration.In dry, ventilation, quiet environment.After the preheating of RBP-1 rat blood pressure instrument, rat is put in the heated at constant temperature case behind preheating 10～15min, measure systolic pressure, heart rate, each time point is surveyed 3 times, gets mean.Blood pressure, heart rate measurement carry out at following time point: the 1st, 2,3,4 weekends after the 4th weekend, the administration before the operation, after the operation.Blood pressure determination after the administration should begin to carry out by 2h after administration.
2. statistical procedures: adopt SPSS software to carry out statistical analysis, experimental result all uses first x ± s to represent, organizes mean more and relatively adopts the ANOVA variance analysis, relatively checks with q between group.There is the significance meaning P≤0.05 for difference.
3 results
4 weeks of postoperative compare with blank model group, and each administration group all has tangible antihypertensive effect, and with respect to aliskiren folk prescription administration group, compound recipe administration group hypotensive effect is remarkable, irritate stomach after 1 week, and blood pressure begins to drop to successive administration 4 weekends (P＜0.05).See Table 1.
The influence of table 1 pair renal hypertensive rat blood pressure
Claims (10)
1. new blood pressure lowering compositions is characterized in that: be to be the Pharmaceutical composition of active component with aliskiren and pharmaceutical salts, hydrate and any 1-2 kind material as described below:
Material 1: calcium ion antagonist (CCB) comprises nifedipine, amlodipine, lercanidipine, felodipine, nilvadipine, lacidipine, nisoldipine and their pharmaceutical salts, optical isomer and hydrate;
Material 2:AT1 receptor antagonist (ARB) comprises valsartan, candesartan Cilexetil, olmesartan medoxomil, irbesartan, losartan, telmisartan, Eprosartan and their pharmaceutical salts, optical isomer and hydrate etc.;
Material 3: angiotensin converting enzyme inhibitor (ACEI) comprises captopril, lisinopril, ramipril, fosinopril, enalapril, benazepril, delapril and their pharmaceutical salts, optical isomer and hydrate etc.;
Material 4: hydrochlorothiazide.
2. the described Pharmaceutical composition of claim 1 is characterized in that, the pharmaceutical salts of aliskiren is a fumarate.
3. the described Pharmaceutical composition of claim 1 is characterized in that the pharmaceutical salts of calcium ion antagonist comprises hydrochlorate, mesylate, benzene sulfonate, maleate.
4. the described Pharmaceutical composition of claim 1, it is characterized in that: compositions is: aliskiren+Levamlodipine Besylate; Aliskiren+Levamlodipine Besylate+hydrochlorothiazide; Aliskiren+Levamlodipine Besylate+valsartan; Aliskiren+captopril,
Aliskiren+hydrochlorothiazide+captopril.
5. the described Pharmaceutical composition of claim 1, it is characterized in that: the unit consumption of aliskiren is 37.5-1200mg, preferred dose is 150-300mg.
6. the described Pharmaceutical composition of claim 1 is characterized in that: the unit consumption of calcium ion antagonist (CCB) is,
The unit consumption of Levamlodipine Besylate is 1.25-40mg, and preferred dose is 5-10mg;
The unit consumption of nifedipine is 1.25-40mg, is preferably 5-10mg;
The unit consumption of lercanidipine is 2.5-80mg, is preferably 10-20mg;
The unit consumption of felodipine is 2.5-80mg, is preferably 10-20mg;
The unit consumption of nilvadipine is 0.5-16mg, is preferably 2-4mg;
The unit consumption of lacidipine is 1-24mg, is preferably 4-6mg;
The unit consumption of Manidipine is 1.25-40mg, is preferably 5-10mg.
7. the described Pharmaceutical composition of claim 1, it is characterized in that: the unit consumption of AT1 receptor antagonist (ARB) is:
The unit consumption of olmesartan medoxomil is 5-160mg, is preferably 10-80mg;
The unit consumption of irbesartan is 37.5-600mg, is preferably 75-300mg;
The unit consumption of candesartan Cilexetil is 1-32mg, is preferably 2-16mg;
The unit consumption of Losartan Potassium is 12.5-200mg, is preferably 25-100mg;
The unit consumption of telmisartan is 10-320mg, is preferably 20-160mg;
The unit consumption of valsartan is 20-320mg, is preferably 40-160mg;
The unit consumption of Eprosartan is 100-1200mg, is preferably 200-600mg.
8. the described Pharmaceutical composition of claim 1, it is characterized in that: the unit consumption of angiotensin converting enzyme inhibitor (ACEI) is:
The unit consumption of captopril is 6.25-100mg, is preferably 12.5-50mg;
The unit consumption of lisinopril is 5-80mg, is preferably 10-40mgmg;
The unit consumption of ramipril is 0.5-20mg, is preferably 1.25-10mg;
The unit consumption of fosinopril is 5-80mg, is preferably 10-40mg;
The unit consumption of enalapril is 1.25-40mg, is preferably 2.5-20mg;
The unit consumption of benazepril is 5-80mg, is preferably 10-40mg;
The unit consumption of delapril is 15-120mg, is preferably 7.5-60mg.
9. the described Pharmaceutical composition of claim 1, it is characterized in that: the unit consumption of hydrochlorothiazide is 5-200mg, preferred dose is 25-50mg.
10. the described Pharmaceutical composition of claim 1 is characterized in that: can be made into oral formulations, comprise granule, tablet, capsule, drop pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101418478A CN102247344A (en) | 2011-05-30 | 2011-05-30 | Novel blood pressure reducing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101418478A CN102247344A (en) | 2011-05-30 | 2011-05-30 | Novel blood pressure reducing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102247344A true CN102247344A (en) | 2011-11-23 |
Family
ID=44975155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101418478A Pending CN102247344A (en) | 2011-05-30 | 2011-05-30 | Novel blood pressure reducing composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102247344A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102430109A (en) * | 2011-12-02 | 2012-05-02 | 邬林祥 | Amlodipine, aliskiren and pril compound antihypertensive drug |
| CN102552276A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Levoamlodipine, aliskiren and hydrochlorothiazide compound antihypertensive medicine |
| CN102552255A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Amlodipine, aliskiren and sartan compound antihypertensive medicine |
| CN102552873A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Levoamlodipine, aliskiren and pril compound antihypertensive medicine |
| CN102552911A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Levoamlodipine, aliskiren and sartan compound antihypertensive medicine |
| CN107029208A (en) * | 2017-06-13 | 2017-08-11 | 江苏黄河药业股份有限公司 | It is a kind of to treat lisinopril compound preparation of angiocardiopathy and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1655819A (en) * | 2002-05-17 | 2005-08-17 | 诺瓦提斯公司 | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| WO2010033954A2 (en) * | 2008-09-22 | 2010-03-25 | Novartis Ag | Galenical formulations of organic compounds |
| CN101700237A (en) * | 2009-09-26 | 2010-05-05 | 吴光彦 | Combined capsule filled with hydrochlorothiazide solid preparation and Aliskiren solid preparation |
| CN101808665A (en) * | 2007-09-28 | 2010-08-18 | 诺瓦提斯公司 | The drug regimen of aliskiren and valsartan |
| CN101926793A (en) * | 2010-08-05 | 2010-12-29 | 成都自豪药业有限公司 | A kind of combined medicine containing telmisartan and Aliskiren and preparation method thereof |
| CN101990428A (en) * | 2008-04-10 | 2011-03-23 | 韩兀生物制药株式会社 | Pharmaceutical formulation |
-
2011
- 2011-05-30 CN CN2011101418478A patent/CN102247344A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1655819A (en) * | 2002-05-17 | 2005-08-17 | 诺瓦提斯公司 | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| CN101808665A (en) * | 2007-09-28 | 2010-08-18 | 诺瓦提斯公司 | The drug regimen of aliskiren and valsartan |
| CN101990428A (en) * | 2008-04-10 | 2011-03-23 | 韩兀生物制药株式会社 | Pharmaceutical formulation |
| WO2010033954A2 (en) * | 2008-09-22 | 2010-03-25 | Novartis Ag | Galenical formulations of organic compounds |
| CN101700237A (en) * | 2009-09-26 | 2010-05-05 | 吴光彦 | Combined capsule filled with hydrochlorothiazide solid preparation and Aliskiren solid preparation |
| CN101926793A (en) * | 2010-08-05 | 2010-12-29 | 成都自豪药业有限公司 | A kind of combined medicine containing telmisartan and Aliskiren and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102430109A (en) * | 2011-12-02 | 2012-05-02 | 邬林祥 | Amlodipine, aliskiren and pril compound antihypertensive drug |
| CN102552276A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Levoamlodipine, aliskiren and hydrochlorothiazide compound antihypertensive medicine |
| CN102552255A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Amlodipine, aliskiren and sartan compound antihypertensive medicine |
| CN102552873A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Levoamlodipine, aliskiren and pril compound antihypertensive medicine |
| CN102552911A (en) * | 2011-12-02 | 2012-07-11 | 邬林祥 | Levoamlodipine, aliskiren and sartan compound antihypertensive medicine |
| CN107029208A (en) * | 2017-06-13 | 2017-08-11 | 江苏黄河药业股份有限公司 | It is a kind of to treat lisinopril compound preparation of angiocardiopathy and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102225203A (en) | Pharmaceutical composition used for lowering blood pressure | |
| JP5241228B2 (en) | Multi-layered tablets containing non-steroidal anti-inflammatory drugs, decongestants and less sedating antihistamines | |
| CN102247344A (en) | Novel blood pressure reducing composition | |
| JP5110697B2 (en) | Solid preparation | |
| CN101450211A (en) | Composite antihypertensive preparation | |
| CA2614085A1 (en) | Pharmaceutical dosage form based on an osmotic active ingredient release system comprising an active ingredient combination of nifedipine and/or nisoldipine and an angiotensin ii antagonist | |
| KR20080032616A (en) | Complex preparations for the treatment of cardiovascular diseases using the time difference dosing principle | |
| KR20080039302A (en) | Pharmaceutical composition comprising controlled release of thiazide-based compound and angiotensin-II-receptor blocker | |
| TWI586353B (en) | Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists | |
| CN101416966B (en) | Medical composition capable of treating hypertension | |
| CN102342944A (en) | Medicament composition for treating hypertension | |
| WO2008148359A1 (en) | The therapeutic uses of imidazol-5-carboxylic acid derivatives | |
| CA2761795C (en) | Burst drug release compositions | |
| CN103565807B (en) | A kind of olmesartan medoxomil/amlodipinepharmaceutical pharmaceutical composition | |
| CN101849942B (en) | Pharmaceutical composition for treating hypertension | |
| CN101313907A (en) | Medicament composition for treating hyperpiesis | |
| JP4871258B2 (en) | Prolonged-release composition comprising toracemide and a matrix-forming polymer | |
| CN103721259A (en) | Angiotensin II receptor blocker/thiazide diuretics/5-methyltetrahydrofolate pharmaceutical composition | |
| CN102949398A (en) | Hypotensive compound preparation and preparation method thereof | |
| US20200297642A1 (en) | Burst drug release compositions | |
| KR20200048516A (en) | A pharmaceutical composition of combination | |
| CN102949726A (en) | Medicinal composition | |
| CN107072977B (en) | NEP inhibitor drug combination and its application | |
| CN201668750U (en) | Compound amlodipine, valsartan and hydrochlorothiazide capsule | |
| WO2013091574A1 (en) | Pharmaceutical composition comprising candesartan or ester thereof and chlortalidone, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111123 |